CBL0137 HCl Protocol: Handling, Dissolution & Assay Use

CBL0137 HCl is a potent small-molecule inhibitor of the FACT (Facilitates Chromatin Transcription) histone chaperone complex used in oncology research to investigate chromatin remodeling, NF-κB pathway suppression, and p53 activation in cancer cell models.

Catalog Number

C414023

Selleck Reference Number

S8483

Primary Target

FACT complex (SPT16/SSRP1 histone chaperone)

Recommended Solvent

DMSO (for stock solution preparation)

Storage Conditions

-20 °C, desiccated, protected from light

Compound Class

Curaxin / DNA-intercalating agent

Overview and Mechanism of Action

CBL0137 HCl (also known as Curaxin-137) is a carbazole-based small molecule that exerts its antitumor activity primarily through inhibition of the FACT (Facilitates Chromatin Transcription) complex, a histone chaperone composed of SPT16 and SSRP1 subunits. By intercalating into DNA, CBL0137 traps FACT on chromatin, preventing its normal function in nucleosome disassembly and reassembly. This dual mechanism simultaneously activates p53 (by blocking its MDM2-mediated degradation indirectly through FACT inhibition) and suppresses the NF-κB signaling pathway, making it a valuable tool compound for studying oncogenic transcriptional programs.

Because CBL0137 acts at the level of chromatin organization rather than through direct kinase inhibition, it is broadly applicable across cancer cell lines that overexpress FACT subunits, including certain pediatric tumors, glioblastoma, and hematologic malignancies.

Stock Solution Preparation

CBL0137 HCl is supplied as a solid and should be handled under standard laboratory safety precautions. To prepare a stock solution, follow these steps:

1. Weigh the compound: Allow the vial to equilibrate to room temperature (approximately 15–20 minutes) before opening to prevent moisture condensation on the powder.
2. Select solvent: DMSO is the recommended primary solvent for CBL0137 HCl. The compound has acceptable solubility in DMSO at concentrations typically used for stock solutions (e.g., 10–50 mM). If aqueous solubility is required for a specific assay, a DMSO stock may be further diluted into aqueous buffer; ensure the final DMSO concentration in cell culture does not exceed 0.1% (v/v) to avoid cytotoxic artifacts.
3. Dissolve: Add DMSO to the weighed powder. Vortex briefly and, if necessary, warm to 37 °C in a water bath for up to 5 minutes to aid dissolution. Do not use ultrasound for extended periods as this may degrade the compound.
4. Aliquot: Divide the stock solution into single-use aliquots to minimize freeze–thaw cycles. Label aliquots with compound name, concentration, solvent, and date of preparation.
5. Store: Store aliquots at −20 °C, desiccated and protected from light. Avoid repeated freeze–thaw cycles (maximum 3 recommended).

Note: Actual solubility values should be verified experimentally. Refer to the Certificate of Analysis (CoA) supplied with the specific lot for purity data.

In Vitro and Cell-Based Assay Guidance

CBL0137 HCl is suitable for a range of in vitro and cell-based assay formats, including viability assays (MTT, CellTiter-Glo), apoptosis assays (Annexin V/PI flow cytometry), reporter gene assays for NF-κB or p53 transcriptional activity, and chromatin immunoprecipitation (ChIP) experiments targeting FACT subunit occupancy.

General Workflow

1. Plate cells: Seed cells at an appropriate density (e.g., 3,000–10,000 cells per well in a 96-well plate, depending on doubling time) and allow attachment overnight before treatment.
2. Prepare working dilutions: Dilute the DMSO stock in complete culture medium immediately before use. Prepare a serial dilution series (e.g., 0.01–10 µM) to establish dose–response curves.
3. Treat cells: Replace medium with treatment medium containing CBL0137 HCl at desired concentrations. Include vehicle control (equivalent DMSO concentration) and positive/negative controls in each experiment.
4. Incubation: Typical treatment durations range from 24 to 72 hours depending on endpoint. Refer to published literature for cell-line-specific conditions.
5. Endpoint analysis: Proceed with downstream assays (viability, Western blot for p53/FACT subunits, qPCR for NF-κB target genes, etc.) according to validated standard protocols.

Tip: Because CBL0137 is light-sensitive, minimize exposure of prepared solutions to ambient light during handling and assay setup.

Safety, Handling, and Waste Disposal

CBL0137 HCl should be handled as a potentially hazardous research chemical. The following precautions are recommended:

• Personal Protective Equipment (PPE): Wear nitrile gloves, laboratory coat, and safety glasses when handling the solid compound or concentrated solutions.
• Containment: Weigh and dissolve the compound inside a chemical fume hood or biosafety cabinet to minimize inhalation of fine particles.
• Skin and eye contact: In case of skin or eye contact, immediately flush with copious amounts of water for at least 15 minutes and seek medical advice.
• DMSO awareness: DMSO can rapidly penetrate intact skin and may carry dissolved compounds transdermally. Exercise particular caution when handling DMSO-dissolved CBL0137 stock solutions.
• Waste disposal: Dispose of compound-containing waste in accordance with your institution's chemical waste regulations. Do not dispose of DMSO solutions down the drain. Consult your institution's Environmental Health and Safety (EHS) office for guidance specific to your locality.

Note: A formal Safety Data Sheet (SDS) should be consulted prior to handling. Contact Aladdin Scientific or refer to the product page for the current SDS.

Quality Control and Troubleshooting

To ensure reproducible results with CBL0137 HCl, implement the following quality-control and troubleshooting measures:

Issue	Possible Cause	Recommended Action
Poor or incomplete dissolution	Insufficient solvent, low temperature	Warm to 37 °C briefly; ensure DMSO is anhydrous
Loss of activity over time	Repeated freeze–thaw, light exposure	Use single-use aliquots; store at −20 °C in the dark
Inconsistent cell viability results	DMSO toxicity, uneven cell seeding	Confirm DMSO ≤0.1% v/v; standardize seeding density
Unexpected p53 activation absent	p53-null or mutant cell line used	Verify p53 status of cell line prior to experiment
NF-κB suppression not observed	Sub-optimal concentration or time point	Perform dose- and time-course optimization

Always verify compound purity via the Certificate of Analysis (CoA) for each lot. If results are inconsistent across lots, contact Aladdin Scientific technical support for assistance.

Frequently asked questions

What is the recommended solvent for preparing a CBL0137 HCl stock solution?

DMSO is the recommended solvent for CBL0137 HCl stock solution preparation. For cell-based assays, dilute the DMSO stock into aqueous culture medium immediately before use, ensuring the final DMSO concentration does not exceed 0.1% (v/v) to prevent cytotoxic effects.

What are the optimal storage conditions for CBL0137 HCl?

CBL0137 HCl should be stored at −20 °C in a desiccated environment, protected from light. It is advisable to prepare single-use aliquots to minimize freeze–thaw cycles, with a recommended maximum of three freeze–thaw cycles to preserve compound integrity.

Which signaling pathways does CBL0137 HCl modulate, and why is this relevant for cancer research?

CBL0137 HCl inhibits the FACT histone chaperone complex, which simultaneously leads to p53 pathway activation and NF-κB pathway suppression. Since both pathways are critical regulators of cell survival, apoptosis, and inflammation in cancer, CBL0137 is a valuable tool for dissecting FACT-dependent transcriptional control in oncology models.

How should I confirm that CBL0137 HCl is active in my cell model?

A positive control for CBL0137 activity can include Western blot analysis for increased p53 protein levels or decreased NF-κB target gene expression (e.g., IL-6, IL-8) following treatment. Verifying the p53 status of the cell line is essential, as p53-null or p53-mutant lines will not show p53-mediated responses.

References

1. Gurova K et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-κB-dependent mechanism of p53 suppression in tumors. Proceedings of the National Academy of Sciences. 2005.
2. Burkhart C et al. Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT. Science Translational Medicine. 2014.
3. Safina A et al. FACT is a sensor of DNA torsional stress in eukaryotic cells. Nucleic Acids Research. 2017.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.